SCYX SCYNEXIS INC

SCYNEXIS to Participate in Piper Sandler and Evercore ISI Conferences

SCYNEXIS to Participate in Piper Sandler and Evercore ISI Conferences

JERSEY CITY, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the Company’s participation in Piper Sandler’s 32nd Annual Virtual Healthcare Conference. Presentations will be available for registered attendees via the Piper Sandler conference site from November 23 to December 3, 2020. The Company will also participate in a panel discussion at Evercore ISI’s 3rd Annual HealthCONx Conference taking place on December 2, 2020.

Presentation details:

Piper Sandler 32nd Annual Virtual Healthcare Conference:
Presentation Date:Monday, November 23 to Thursday, December 3, 2020
Presentation Time:8:00 a.m. – 5:00 p.m. ET
Webcast:

 
Evercore ISI 3rd Annual HealthCONx Conference:
Panel Discussion Topic:

No Fungus Among Us: Addressing an Important Need with Cidara, F2G, and SCYNEXIS

Presentation Date:Wednesday, December 2, 2020
Presentation Time:11:20 a.m. – 12:05 p.m. ET
 

A webcast of both presentation recordings will be available for 30 days and can be found on the Scynexis website at: .

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to potentially help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. Our lead candidate, ibrexafungerp (formerly known as SCY-078), is a broad-spectrum, IV/oral antifungal agent representing a novel therapeutic class, in late stage development for multiple indications, ranging from vaginal yeast infections to life-threatening fungal infections in hospitalized patients. The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization. For more information, visit .

CONTACT: 

Investor Relations

Irina Koffler

LifeSci Advisors

Tel: (646) 970-4681

Media Relations

Gloria Gasaatura

LifeSci Communications

Tel: (646) 970-4688

 



EN
24/11/2020

Underlying

SCYXSCYNEXIS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SCYNEXIS INC

 PRESS RELEASE
Free
SCYX SCYNEXIS INC

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Co...

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical hold, triggering a $10M milestone payment from GSK. An additional $20M milestone will be triggered upon the six month anniversary of the new patient dosing; as previously disclosed GSK disputes these milestone payments.  SCYNEXIS vigorously disagrees with GSK’s position and is working towards resolving this disagreement; SCYNEXIS is actively working with GSK to transfer the BREXAFEMME New Drug Application (NDA) to G...

8h / 15m 1 EN
 PRESS RELEASE
Free
SCYX SCYNEXIS INC

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical holdResumption of dosing in this study triggers a $10M milestone payment from GSK plus an additional $20M milestone due in six months; as previously disclosed GSK disputes these milestone payments, and SCYNEXIS vigorously disagrees with their position JERSEY CITY, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant i...

May 28, 2025 1 EN
 PRESS RELEASE
Free
SCYX SCYNEXIS INC

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Cor...

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update Ibrexafungerp clinical hold lifted by the FDA. SCYNEXIS working to resolve a disagreement with GSK involving the restart of the MARIO study. GSK remains committed to the commercialization of Brexafemme.Hansoh recently received Chinese (NMPA) approval for ibrexafungerp in the treatment of acute VVC. SCYNEXIS will receive a milestone payment from Hansoh upon commercialization as well as royalties of approximately 10% on China sales.Presented positive preclinical data for its second-generation fungerp candidate...

May 15, 2025 1 EN
 PRESS RELEASE
Free
SCYX SCYNEXIS INC

SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fung...

SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) JERSEY CITY, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second-generation fungerp candidate SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) in Vienna, Aus...

April 8, 2025 1 EN
 PRESS RELEASE
Free
SCYX SCYNEXIS INC

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corpora...

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in Q3 of 2025.Four presentations for SCY-247 were accepted by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) congress, April 11-15, 2025 in Vienna, Austria.SCYNEXIS continues to make progress towards the restart of the Phase 3 MARIO study in invasive candidiasis. The Company anticipates the restart, pending the FDA’s lifting of the cl...

March 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch